利福平联合头孢曲松治疗儿童大叶性肺炎的疗效观察

目的 探讨头孢曲松联合利福平对儿童大叶性肺炎的疗效及安全性。方法 入组西安市中心医院收治的患者78例，随机分为观察组（n=39）和对照组（n=39）。对照组静脉给予注射用头孢曲松钠，每次80 mg/kg，每日1次。观察组在对照组基础上口服利福平胶囊，每次10~20 mg/kg，每日1次。两组疗程均为7~14 d。比较两组患者（研究药物自初次给药时间的8~15 d）的临床治愈率，炎症因子白介素-6（IL-6）、白介素-10（IL-10）、C反应蛋白（CRP）、高迁移率族蛋白B1（HMGB1）水平及不良反应。结果 观察组和对照组临床有效率分别为87.2%、66.7%，两组疗效有统计学差异（P<0.05）。与治疗前比较，两组患儿治疗后血清IL-6、IL-10、CRP、HMGB1均显著下降，同组治疗前后比较差异有统计学意义（P<0.05）；且观察组显著低于对照组，差异有统计学意义（P<0.05）。两组不良事件发生率，没有统计学差异。结论 利福平联合头孢曲松治疗儿童大叶性肺炎疗效确切，安全性好，值得临床应用推广。

Therapeutic effect of ceftriaxone combined with rifampicin on lobar pneumonia in children

Objective To investigate the efficacy and safety of ceftriaxone and rifampin in children with lobar pneumonia.Methods A total of 78 patients admitted to our hospital were randomly divided into observation group (n=39) and control group (n=39). The observation group was treated with ceftriaxone and rifampicin. The control group was treated with ceftriaxone. The two groups of treatment were 7 to 14 days.We compared clinical cure at the test-of-cure visit (study drug delivery time between 8 and 15 days) between two groups.Results During the follow-up of the cure test, the clinical cure rates in the observation group and the control group were 34 (87.2%) and 26 (66.7%) respectively, with statistically significant differences between the two groups (P<0.05). The incidence of adverse events in both groups were similar, and there were no statistical difference between two groups.Conclusion Ceftriaxone combined with rifampicin to treat pediatric lobar pneumonia is effective and safe, and it is worth promoting the clinical application.